Oncogenic tetraspanins: Implications for metastasis, drug resistance, cancer stem cell maintenance and diagnosis of leading cancers in females

Marni, Rakshmitha; Chakraborty, Anindita; Malla, Rama Rao

doi:10.1016/j.genrep.2022.101548

Cited by 3 publications

(2 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formerly, members of the human tetraspanin family have been patented and used to treat cancer, allergic diseases, and anaphylaxis. 11,12 To the best of our knowledge, there has been no previous study of the direct antibacterial activity of tetraspanin peptides against P. aeruginosa.…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial effect of Tetraspanin CD9 Peptides on Pseudomonas aeruginosa

Murad,

Ab-Rahim,

Al-Talib

2023

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

It is critical to find an alternative therapeutic approach to combat Pseudomonas aeruginosa (P. aeruginosa) that can simultaneously reduce the occurrence of bacterial resistance. The tetraspanin CD9, a highly expressed membrane protein in melanocytes was chosen for this study because it is highly expressed in keratinocytes and has been implicated in the pathogenesis of bacterial infections in a previous study. The antimicrobial activity of CD9 peptides against the standard strain P. aeruginosa (ATCC 27853) and a clinical multidrug-resistant P. aeruginosa (MDR- P. aeruginosa) was studied using the disc diffusion method. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of CD9 peptides were determined by broth microdilution assays with concentrations ranging from 1 mg/mL to 4.88×10-4 mg/mL. The antibiofilm activity of the CD9 peptides was also determined. CD9 peptides showed an 11.75 ± 2.36 mm inhibition zone against the standard P. aeruginosa strain but none against the MDR- P. aeruginosa. Both isolates had the same MIC value, 0.25 mg/mL. The MBC for the standard strain P. aeruginosa was 0.5 mg/mL, while for the MDR- P. aeruginosa strain, it was 1 mg/mL. CD9 peptides significantly inhibited up to 70% biofilm against both P. aeruginosa isolates. CD9 peptides showed a modest inhibitory effect against the standard strain P. aeruginosa but not against MDR- P. aeruginosa. Interestingly, CD9 peptides were found to be a good anti-biofilm treatment against both P. aeruginosa isolates. This study demonstrated that CD9 peptides have the potential to be an alternative antimicrobial treatment against P. aeruginosa.

show abstract

Section: Introductionmentioning

confidence: 99%

Antimicrobial effect of Tetraspanin CD9 Peptides on Pseudomonas aeruginosa

Murad,

Ab-Rahim,

Al-Talib

2023

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Given the broad tissue distribution and expression, tetraspanins have been discovered to be involved as molecular organisers within the extracellular loop region for viral entry and bacterial adhesion to host cells by interacting with bacterial cells via receptors for bacterial adhesins, subsequently leading to the pathogenesis (13,21,22). In the past, a tetraspanin-based treatment has been patented for the treatment of cancer, allergic diseases, and anaphylaxis (23,24). However, to date, there is one limited study investigating the role of tetraspanin CD9 on P. aeruginosa (25,26).…”

Section: Introductionmentioning

confidence: 99%

Unveiling the Anti-Adhesive Potential of Tetraspanin CD9 Peptides againstPseudomonas aeruginosain Human Keratinocytes

Murad,

Ab-Rahim,

Al-Talib

2023

Preprint

View full text Add to dashboard Cite

Multidrug-resistant P. aeruginosa strains are becoming a public health problem worldwide, causing numerous nosocomial infections. Adhesion of bacteria to host cells is a crucial step in infection, hence interruption of this stage can reduce bacterial infection. Tetraspanin CD9 was chosen for this study as it has been implicated in the pathogenesis of bacterial infections in a previous study. The aim of this study is to investigate the adhesion inhibition of tetraspanin CD9 peptides against P. aeruginosa in human keratinocytes. HaCaT cells were infected with P. aeruginosa, prior to treatment with CD9 peptides. The CD9 peptides cytotoxicity testing was determined by MTT assay. Bacterial adhesion was also determined quantitatively by counting viable bacterial cells and qualitatively by Giemsa staining and transmission electron microscope. Inflammatory markers (IL-8 and IL-6) expression was measured by Elisa assay. CD9 peptides did not affect HaCaT cell viability and inflammatory markers release. This study successfully demonstrated that CD9 peptides reduced P. aeruginosa adherence. Colonies produced by P. aeruginosa isolates treated with CD9 peptides were significantly reduced. Giemsa staining and TEM showed that treated samples had lower bacterial density and were located farther from the cells. These data suggest that tetraspanin CD9 peptides as the potential therapeutic approach against P. aeruginosa due to its property that inhibits bacterial adhesion without killing the bacteria, whereby at the same time does not adversely affect the nature of host cells.

show abstract